References
1 Aapro M et al. The effect of guideline-
consistent antiemetic therapy on chemotherapy-
induced nausea and vomiting (CINV): the Pan
European Emesis Registry (PEER). Ann Oncol
2012;23(8):1986–92.
2 Navari RM, Aapro M. Antiemetic prophylaxis
for chemotherapy-induced nausea and vomiting.
N Engl J Med 2016;374:1356–67.
3 Grunberg SM. Incidence of chemotherapy-
induced nausea and emesis after modern
antiemetics. Cancer 2004;100:2261–8.
4 Jordan K et al. Efficacy benefit of an NK1
receptor antagonist (NK1RA) in patients
receiving carboplatin: supportive evidence
with NEPA (a fixed combination of the NK1
RA, netupitant, and palonosetron) and
aprepitant regimens. Support Care Cancer
2016;24(11):4617–25.
5 Herrstedt J et al. 2016 Updated MASCC/ESMO
Consensus Recommendations: Prevention of
Nausea and Vomiting Following High Emetic
Risk Chemotherapy. Support Care Cancer
2017;25(1):277–88.
6 NCCN Clinical Practice Guidelines in Oncology.
Antiemesis. 1.2019.
7 Bosjnak SM, Gralla RJ, Schwartzberg L.
Prevention of chemotherapy-induced nausea:
the role of neurokinin-1 (NK1) receptor
antagonists. Support Care Cancer 2017;Jan
20:doi: 10.1007/s00520-017-3585-z.
8 Hesketh PJ et al. Antiemetics: American
Society of Clinical Oncology clinical practice
guideline update. J Clin Oncol 2018;35(28):
3240–61.
9 Chasen M et al. Rolapitant improves quality
of life of patients receiving highly or moderately
emetogenic chemotherapy. Support Care Cancer
2017;25(1):85–92.
10 Molassiotis A et al. Anticipatory nausea,
risk factors, and its impact on chemotherapy-
induced nausea and vomiting: Results from the
Pan European Emesis Registry Study. J Pain
Symptom Manage 2016;51:987–93.
11 Lopes G et al. Pembrolizumab (pembro)
versus platinum-based chemotherapy (chemo)
as first-line therapy for advanced/metastatic
NSCLC with a PD-L1 tumor proportion score
(TPS) ≥1%: Open-label, phase 3 KEYNOTE-042
study. J Clin Oncol 2018;38(suppl):abstr LBA4.
12 Schwartzberg LS. Chemotherapy-
induced nausea and vomiting: clinician
and patient perspectives. J Support Oncol
2007;5(supplement 1):5–12.
13 Curran MP et al. Aprepitant: a review of its
use in the prevention of nausea and vomiting.
Drugs 2009;69(13):1853–78.
14 Bloechl-Daum B et al. Delayed nausea and
vomiting continue to reduce patients’ quality
of life after highly and moderately emetogenic
chemotherapy despite antiemetic treatment.
J Clin Oncol 2006;24:4472–8.
15 Haiderali A et al. Impact on daily functioning
and indirect / direct costs associated with
chemotherapy-induced nausea and vomiting
(CINV) in a US population. Support Care Cancer
2011;19:843–51.
16 Carver C et al. Clinical and economic burden
of chemotherapy-induced nausea and vomiting
among patients with cancer in a hospital
outpatient setting in the United States. J Med
Econ 2011;14:87–98.
17 Turini M et al. An assessment of
chemotherapy-induced nausea and vomiting
direct costs in three EU countries. Drugs
Context 2015;4:212285.
18 Jordan K et al. International antiemetic
guidelines on chemotherapy induced
nausea and vomiting (CINV): Content and
implementation in daily routine practice. Eur
J Pharmacol 2014;722:197–202.
19 Aapro M et al. NEPA, a fixed oral combination
of netupitant and palonosetron, improves control
of chemotherapy-induced nausea and vomiting
(CINV) over multiple cycles of chemotherapy:
results of a randomized, double-blind, phase
3 trial versus oral palonosetron. Support Care
Cancer 2017;25(4):1127–35.
20 Gralla E. Palonosetron improves prevention
of chemotherapy-induced nausea and
vomiting following moderately emetogenic
chemotherapy: results of a double-blind
randomized phase III trial comparing single
doses of palonosetron with ondansetron.
Ann Oncol 2003;14(10):1570–7
21 Eisenberg P. Improved prevention of
moderately emetogenic chemotherapy-induced
nausea and vomiting with palonosetron,
a pharmacologically novel 5-HT3 receptor
antagonist. Cancer 2003;98:2473–82
22 Aapro M et al. A phase III, double-blind,
randomized trial of palonosetron compared
with ondansetron in preventing chemotherapy-
induced nausea and vomiting following highly
emetogenic chemotherapy. 2006 Ann Oncol
17;1441–9.
23 Saito M. Palonosetron plus dexamethasone
versus granisetron plus dexamethasone for
prevention of nausea and vomiting during
chemotherapy: a double-blind, double-dummy,
randomised, comparative phase III trial. Lancet
Oncol 2009;10:115–24.
hospitalpharmacyeurope.com | 2019 | 41